Calendario›REGN›REGN5381
REGN5381
REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure
Ensayo de REGENERON PHARMACEUTICALS, INC. en Insuficiencia cardiaca.
Más ensayos de: Insuficiencia cardiaca.
- Fase
- Fase 2
- Estado
- Completado
- Participantes
- 59
- Centros
- 1
- Fin del objetivo primario
- jun 2025
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en jun 2022.
Qué mide
Number of Participants With Treatment-emergent Adverse Events (TEAEs) (From first dose (Day 1) up to end of study (Day 126)) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis study is researching an experimental drug called REGN5381, further referred to as study drug. The study is focused on adult participants with heart failure that, in the opinion of the study doctor, have a clinical indication for right heart catheterization (RHC). The aim of the study is to evaluate the safety and tolerability of the study drug. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Más ensayos de REGN
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| cemiplimab | Fase 2 | En marcha, sin reclutar | mar 2025 (real) |
| Pozelimab + Cemdisiran · NIMBLE | Fase 3 | En marcha, sin reclutar | jul 2025 (real) |
| Garetosmab · OPTIMA | Fase 3 | En marcha, sin reclutar | jul 2025 (real) |
| Aflibercept 8 mg · ELARA | Fase 3 | En marcha, sin reclutar | ago 2025 (real) |
| Dupilumab · ENGAGE | Fase 2 | En marcha, sin reclutar | feb 2026 (real) |
| Fianlimab | Fase 3 | En marcha, sin reclutar | mar 2026 (real) |
Todos los de REGN, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT05353166), actualizada en sep 2026.